Navigation Links
Lilly CEO Lechleiter Calls for Repair of the 'Engine of Biopharma Innovation'
Date:10/30/2009

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- In a speech today to the City Club of San Diego, John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY), said that the engine of biopharmaceutical innovation is "broken." He offered a vision for biopharmaceutical companies to "reinvent innovation" to make the most of today's wealth of scientific knowledge to benefit patients and address unmet medical needs. Lechleiter's remarks came the day after his company dedicated a state-of-the-art biotechnology center in San Diego.

"At a time when the world desperately needs more new medicines - for everything from H1N1 to Alzheimer's disease - we're taking too long, spending too much and producing far too little," said Lechleiter, whose company is headquartered in Indianapolis, Ind. "Repowering pharmaceutical innovation is an urgent need not only for our company and our industry but for our nation - and for communities like San Diego and Indianapolis that have a huge stake in the life sciences. We remain dependent on a society that welcomes and values new ideas, and public policy that enables innovation to be rewarded for the value it creates. But we also know that we need to change."

Addressing the audience of business leaders that included many from San Diego's biotech community, Lechleiter said that biopharmaceutical research and development reduces medical costs, improves Americans' health, and provides many high-paying jobs. But despite its value to health care, he said, the biopharma industry is losing its advantage and wasting its potential. Noting the current debate on health care reform, he stressed the need for public policy that enables and rewards medical innovation that can help rein in health care costs and improve quality.

Lechleiter outlined major challenges the industry must overcome:

  • A loss of trust in product safety and in the honesty of pharmaceutical businesses, for which he said "we mostly have ourselves to blame";
  • A risk-averse policy and regulatory environment that has led to high hurdles for new medicines that could benefit patients; and
  • The pressures of the health care system, where the industry has become an attractive target for policy makers looking for cost savings, even as prescription drugs account for only 10 percent of health care spending.

Lechleiter said that instead of wasting time complaining about these external pressures, however, biopharma companies must change the way they develop new medicines.

He suggested three "C's" for revitalizing medical innovation:

  • Collaboration: breaking down the walls to work with other large and small enterprises and with academic and government researchers, worldwide;
  • Competency: employing advanced scientific tools to take advantage of the explosion of knowledge in human biology; and
  • Culture: putting patients and improved outcomes at the center of research from the very beginning of the drug development process.

Lechleiter cited Lilly initiatives in each area:

  • Lilly's Fully Integrated Pharmaceutical Network (FIPNet) model to access ideas, resources, and talent beyond its walls, including extensive collaboration with biotech firms and academic research centers in San Diego;
  • The company's use of advanced analytics and clinical trial designs, and its new Development Center of Excellence, to streamline the development of new medicines, and its focus on tailored therapeutics to improve outcomes for individual patients; and
  • Lilly's efforts to create a culture with a sharp focus on patients and a "new spirit of urgency."

He concluded that reinventing biopharmaceutical research and development in these ways would help regain the public's trust, address the concerns of regulators and demonstrate to policymakers the value that innovative medicines can and must play.

Yesterday Lilly, one of the world's leading biopharmaceutical research companies, opened the "Lilly Biotechnology Center - San Diego."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about several investigational compounds for the treatment of autoimmune diseases and reflects Lilly's current beliefs. However, as with any pharmaceutical product under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the products will receive regulatory approval, or that the regulatory approval will be for the indications anticipated by the company. There is also no guarantee that the products will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):